Page 5, line 19, after "*E.coli.*" insert -1, and Seq. Id. No. 4 shows the corresponding amino acid sequence.--.

A4

Page 6, line 20, delete "extracytoplamic" and insert --extracytoplasmic-- in its place.

Page 7, line 7, delete "extracytoplamic" and insert --extracytoplasmic-- in its place.

IN THE CLAIMS:

Please cancel claims 18 and 19 without prejudice.

Please amend the claims as follows:

Claim 3, line 1 (page 30, line 10) delete "or 2".

Claim 4, line 1 (page 30, line 13), delete ", 2 or 3".

6. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the protein encoded by the mutant gene is SurA.

A4

7. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the bacterium is further attenuated by a non-reverting mutation in a second gene.

Sub B1

10. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the mutation in the gene encoding a protein which promotes folding of extracytoplasmic proteins [and/or the mutation in the second gene] is a defined mutation.

A5 Cont Sub B1

11. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the bacterium has no uncharacterised mutations in the genome thereof.

A5 cmld. Sub EA

12. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the bacterium is a bacterium that infects via the oral route.

13. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the bacterium is from the genera Salmonella, Escherichia, Vibrio, Haemophilus, Neisseria, Yersinia, Bordetella or Brucella.

A6 Sub EB

15. (Amended) A vaccine according to [any one of the preceding claims] claim 1 wherein the bacterium is genetically engineered to express an antigen from another organism.

A7 Sub EC

17. (Amended) A vaccine according to claim 15 [or 16] wherein expression of the antigen is driven by the *nirB* promoter or the *htrA* promoter.

Please add the following new claims:

--21. A vaccine according to claim 2 wherein the protein encoded by the mutant gene promotes the folding of secreted proteins.

A8 Cm't

22. A vaccine according to claim 6 wherein the bacterium is further attenuated by a non-reverting mutation in a second gene.

23. A vaccine according to claim 22 wherein the second gene is an *aro* gene, a *pur* gene, the *htrA* gene, the *ompR* gene, the *galE* gene, the *cya* gene, the *crp* gene or the *phoP* gene.

24. A vaccine according to claim 23 wherein the *aro* gene is *aroA*, *aroC*, *aroD* or *aroE*.

25. A vaccine according to claim 7 wherein the mutation in the second gene is a defined mutation.

26. A vaccine according to claim 22 wherein the mutation in the second gene is a defined mutation.

27. A vaccine according to claim 16 wherein expression of the antigen is driven by the *nirB* promoter or the *htrA* promoter.

28. A method of vaccinating an animal comprising administering a vaccine according to claim 1.

29. A method according to claim 28 wherein the animal is a human.

30. A method of manufacturing a vaccine comprising providing a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins and adding a pharmaceutically acceptable carrier or diluent.--